Xin Luo

机构：Pfizer (United States) · ORCID：0000-0002-4592-6734

发表论文 88 篇 · 总被引 636 次 · h-index 15

代表论文

Metabolic landscape and pathogenic insights: a comprehensive analysis of high ovarian response in infertile women undergoing in vitro fertilization (2024 · Journal of Ovarian Research · 被引 16)
Decabromodiphenyl ethane exposure-mediated mitochondrial dysfunction drives oxeiptosis in placental trophoblasts and induces fetal growth restriction (2025 · Journal of Environmental Management · 被引 15)
Predicting treatment response and prognosis of immune checkpoint inhibitors-based combination therapy in advanced hepatocellular carcinoma using a longitudinal CT-based radiomics model: a multicenter study (2025 · BMC Cancer · 被引 12)
MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancer (2024 · Journal of Clinical Investigation · 被引 9)
Transcription factor EB, a promising therapeutic target in cardiovascular disease (2024 · PeerJ · 被引 8)
Lactate‐mitochondrial crosstalk: A new direction in the treatment of sepsis‐induced acute kidney injury (2024 · Cell Biology International · 被引 8)